Vixticibart clinical trials
Also written REGN5381.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses vixticibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- REGN5381
- 4
Studies by the year they started
4 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses vixticibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge PressureCompletedPhase 2Regeneron PharmaceuticalsNCT05353166Written as REGN5381
- REGN5381 in Adult Participants With Heart Failure With Reduced Ejection FractionTerminatedPhase 2Regeneron PharmaceuticalsNCT06237309Written as REGN5381
- REGN5381 in Adult Participants With Uncontrolled HypertensionTerminatedPhase 2Regeneron PharmaceuticalsNCT06833190Written as REGN5381
- Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult HumansCompletedPhase 1Regeneron PharmaceuticalsNCT04506645Written as REGN5381
Given beside what is tested · 1 — vixticibart is usual care or a partner of the new treatment
Codes
What other systems call vixticibart · ClinicalTrials.gg INT014655
- UNII (FDA) 3E5N6X8CJFVIXTICIBARTOne source FDA
- NCI Thesaurus C207014VixticibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3E5N6X8CJF | VIXTICIBART | One source FDA |
| NCI Thesaurus | C207014 | Vixticibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.